CoV-2 SAM (LNP) Vaccine

N/A

Report date: 2026/05/13 11:17:53

Base Information

Drug NameCoV-2 SAM (LNP) Vaccine

Drug Alias NameCoV-2 SAM [LNP] vaccineGSK-4184258A

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > self-amplifying RNA vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsVirus Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc

Inactive CompaniesN/A

Active IndicationsVirus Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A